Merck (MRK) is cutting $3 billion from its annual expenses as it prepares for generic competition to its blockbuster cancer drug, Keytruda.

The company narrowed its full-year sales guidance range, saying it now expects sales in the range of $64.3 billion to $65.3 ...

Merck said it is embarking on a multi-year cost-savings plan, which includes cuts to its workforce and real-estate footprint, ...

On a per-share basis, the Rahway, New Jersey-based company said it had profit of $1.76. Earnings, adjusted for one-time gains and costs, were $2.13 per share. The results topped Wall Street ...

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug ...

Drugmaker Merck & Co on Tuesday announced job and cost cuts it said will save $3 billion a year as it posted lower ...

The company will pay $140.6 million to settle claims that it illegally exported products to China. Separately, Cadence posted higher revenue in the second quarter and boosted its full-year earnings ...

Verona Pharma plc (NASDAQ:VRNA) is one of the best multibagger stocks according to hedge funds. On July 9, 2025, Merck & Co.

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...

Merck has had a successful track record of beating estimates, having surpassed EPS expectations 88% of the time and beating ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

Merck & Co., Inc. (NYSE:MRK) is one of the top low volatility healthcare stocks to buy now. Analyst Daina Graybosch of ...